Table 3.
Comparison between CAR-T KTE-X19 therapy and allo-SCT.
| Study | Approach | N° Patients | Median Age (Range) | N° Prior Lines (Range) | N° Refractory (%) | N° Prior Rituximab (Range) |
N° Prior iBTK (Range) |
ORR/CR | Median FU | 1-yr NRM | 1-yr PFS | 1-yr OS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hamadani et al. | MAC | 74 | 54 (27–69) | 3 (2–5) | 37 (50) | 11 (52) | 0 | ? | 35 mo | 43% | 31% | 33% |
| Hamadani et al. | RIC/non -myeloablative | 128 | 59 (42–75) | 4 (1–5) | 71 (55) | 52 (80) | 0 | ? | 43 mo | 38% | 38% | 46% |
| Cook et al. | RIC | 70 | 52.2 (34.7–68.8) | 2 (1–6) | 12 (17%) | 40 (64%) | 0 | 51/48% | 37 mo | 18% | ≈50% | ≈75% |
| Le Gouill et al. | RIC | 70 | 56 (33–67.5) | 2 (1–5) | 15 (21%) | ? | 0 | 94%/89% of eval. pts | 24 mo | ≈20% | ? | ≈60% |
| Wang et al. | CAR-T | 68 | 65 (38–79) | 3 (1–5) | 27 (40) | 68 (100) | 68 (100) | 85%/59% | 12.3 mo | 3% | 61% | 83% |